Heng Rui Medicine: On the internationalization of the road to a triumphant legato

--in oxaliplatin through the EU certification August 23, 2012, Jiangsu Heng Rui Pharmaceutical Co., Ltd. (hereinafter referred to as "Heng Rui Medicine") issued a notice: The company received the Netherlands Food and Drug Administration, the company produced injection of Oxaliplatin approved in the Netherlands listed sales. With the approval of the EU certificate of mutual recognition, the company can be marketed in any other EU country. This means that the company has become the first domestic injection of injections approved in the EU listed sales of pharmaceutical companies, from the internationalization of the strategy has taken a new journey. Just last December, the company produced the anti-cancer drug irinotecan injection through the U.S. FDA certification, the U.S. listed as the first Chinese-made injection. Last April, Heng Rui produced the first batch of injections have been sold to the United States, to achieve domestic injections in the U.S. market zero breakthrough. The reporter has just learned from the relevant departments, August 2012 Heng Rui Anti-tumor pharmaceutical preparations international production base has been listed by the National Development and Reform Commission, Ministry of Finance, Ministry of Health and Ministry of 4 ministries and departments of the "2012 General name Chemical Drug development Project support list." Time just a few months, so continuous 0 points breakthrough, so close to the journey to open up, so many "first" ... For the Chinese national pharmaceutical industry, this is a time of national industry strength of the march, is a national industry pride of cohesion, and for walking on the road of innovation and internationalization of Heng Rui, the song of Victory, is the innovation for many years to change, hard pay return and harvest, is always determined to pursue excellence, Affirmation and verification of the international faith and determination. In the face of Chinese drugs, especially injections due to the quality gap by the developed countries in the market, as early as 2006, the company officially launched the preparation of overseas export plans. "Must be the Chinese injection into the European and American markets, we must let the European and American people to recognize the quality of Chinese medicine" for pioneers, need not only courage, but such forward-looking, unwavering belief and determination. Cast the international brand to build the core competitiveness of the enterprise as a national innovation pilot enterprise, the success of Heng Rui Medicine, many people logically believe that scientific and technological innovation is an inexhaustible impetus for enterprise development. But for the people of Heng Rui, the company's internationalization strategy is also the key factor. The root of medicine is quality, brand and quality. Quality is the lifeline of enterprises, is the support point of corporate brand, if a product quality problems, it may lead to the decline of the entire enterprise, but also to the people's lives and safety damage. "The pursuit of excellence, the best way is to participate in the international high standards of competition," the concept has been deep in the hearts of Heng Rui. To take the international road, the first prerequisite is to pass international standards certification. As the world's top law enforcement agency specializing in food and drug management, FDA and the European Union are the most internationally renowned and authoritative drug regulators, representing the world's highest level. To this end, Heng Rui Medicine from the outset to target the FDA and EU certification, but also aimed at the chemicalThe highest level of non terminal sterilization injection was examined in the system of drug certification and inspection. Non-terminal sterilization injection, the use of filtration technology, the entire production process must ensure aseptic operation, which is the chemical production process of the highest requirements, the most difficult risk control of the production process. Certification bodies of this type of product requirements are extremely high, strict inspection, domestic enterprises so far no one dares to challenge. This is a Chinese enterprise has not yet rushed out of the road, in order to get through the Chinese pharmaceutical companies to the international road, Heng Rui people complacent, firm forward. In terms of infrastructure, Heng Rui Medicine in 2000 to build injection workshop in the eyes of the European and American standards, investment in huge sums of money, the use of the world's top production equipment. But in order to meet the requirements of injection production, since 2007, Heng Rui Medicine has invested more than 70 million yuan, the plant facilities, equipment and so on a full range of upgrades, but also particularly increased verification and on-line monitoring equipment for real-time aseptic operation monitoring, to meet aseptic production needs. Hardware is the foundation, software is guaranteed. At the same time, the constant increase in capital investment, Heng Rui Medicine also attaches great importance to system building and personnel training. Europe and the United States certified six major systems, Heng Rui Medicine from including personnel, materials, maternity ward, equipment, SOP (standard operating Procedures), production processes, environmental monitoring, quality control and other aspects of the start, sound institutions, improve the system, strengthen the control of the key aspects of drug production, to ensure drug quality and medication safety. At the same time, in order to ensure the smooth implementation of inspection certification, Heng Rui Medical staff to achieve strict pre-job training and on-the-job continuous training, and constantly improve the overall quality of staff and quality awareness. Time and again input, a transformation, a part of the norms, over and over the training, Heng Rui Pharmaceutical investment in large funds and great strength, for the successful entry of the FDA and the EU certification has laid a solid foundation. To research innovation for the Wings sailing irinotecan and oxaliplatin injection through the FDA and the EU certification, but Heng Rui Medicine for many years development results in a grand glance, is the climax of a few of the highlights. According to the 2011 Annual report of Heng Rui Medicine, the company realized operating income of 4.55 billion yuan in 2011, an increase of 21.53%, the net profit attributable to the shareholders of the listed company is 877 million yuan, the growth of 21.05% per share, the earnings of 0.78 yuan, the weighted average net assets yield of 23.11%. Reporter learned from the relevant departments, this year, Heng Rui was awarded the Southern Institute of Medicine and Economic Research 2011, "The Top ten China's most innovative drug enterprises," and ranked first; at the same time, Heng Rui has been the Chinese Pharmaceutical Industry Information Center for 4 consecutive years as "pharmaceutical listed companies the most competitive 20 enterprises" The most valuable pharmaceutical listed companies ". Such gratifying performance, and Heng Rui more than 40 years along the way to the process intertwined, can not help but cause people to ponder the true meaning behind the great success. From the unknown national drug companies to today's internationalization as a strategy to embark on the broad road of listed companies, a thriving source of inexhaustible power toWhere's the bottom? An indispensable part of the answer is scientific innovation, using technology to control their own destiny. As Heng Rui people often say: "You do not have the technology, your destiny is in the hands of others, we have to seize the fate of their own hands." "The company's annual cost of research and development accounts for 8% to 10% per cent of sales revenue." 2011, the company invested in research and development capital of 420 million yuan, an increase of 30% than the previous year, research and development investment accounted for 9.2% of sales revenue, this level has been close to the international medium-sized pharmaceutical enterprises. At the same time, in order to promote science and technology research and development, to build innovative soul, Heng Rui always adhere to the "talent is the first resource" concept of development, the introduction and training of more than 1300 types of research personnel, the existing 3 national "thousand people Plan Talent", 45 returnees experts, Master and Doctor breakthrough In the introduction of talent, the company from the past only focus on technical personnel to management, marketing and technical personnel, so as to create a more reasonable structure of the leading talent team. Heng Rui to science and technology as the main line, and constantly build and improve the company's core competitiveness, the enterprise not only set up a national "major new drug creation" special incubation base, the National Target Drug Engineering Research Center, but also become the national anti-tumor Drugs Technology Innovation Alliance of the lead unit. So far, the company has undertaken 5 major categories of 15 "major New drug creation" project of innovative topics, dozens of national and provincial and ministerial level science and technology projects, the existing 1 new drugs have been listed sales, 1 innovative drug reporting production, 10 innovative drugs in different clinical stages, with nearly 200 national invention patents and 91 Global patent. The success of oxaliplatin in the EU, let us have reason to believe that the international road of Heng Rui Medicine will continue to accelerate. "Next, we not only to sell Chinese-made drugs abroad, but also to increase scientific and technological innovation, speed up the development of innovative drugs, and ultimately to China's innovative drugs sold around the world to truly shape and enhance the national pharmaceutical brand." Our overall goal is, in 3-5 years time, to achieve the product from imitation to innovation-oriented, market sales from the domestic to the international leap-forward transformation, and strive to make Heng Rui medicine to become China's transnational pharmaceutical enterprises. "Towards this goal, the people of Heng Rui are sailing."